Similar results were noted for all patients with adenocarcinoma histology ( @ patients in the docetaxel plus nintedanib group and @ in the docetaxel plus placebo group ; median overall survival @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @ % CI @-@ -RSB- ; HR @ -LSB- @ % CI @-@ -RSB- , p = @ ) , but not in the total study population ( median @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @-@ -RSB- ; HR @ , @ % CI @-@ , p = @ ) .